The ARF5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed to disrupt endogenous ARF5 gene expression. This polyclonal pool provides a heterogeneous loss-of-function model for studying ARF5-mediated cellular processes without clonal selection, thus preserving biological variability inherent to the knockout population. The product offers a robust tool for investigating the roles of the small GTPase ARF5 in membrane trafficking and cancer cell physiology.
The host A-549 cell line originates from a 58-year-old male with lung adenocarcinoma and has been widely employed as an epithelial carcinoma model. These adherent cells maintain key features of alveolar type II epithelial cells, including the expression of multiple trafficking and signaling components. Their well-characterized growth properties, tumorigenic potential, and responsiveness to pharmacological perturbations make A-549 an ideal background for dissecting ARF5-dependent pathways in a cancer-relevant context.
ARF5 belongs to the ADP-ribosylation factor family of small GTPases that cycle between inactive GDP-bound and active GTP-bound conformations. Activation is mediated by Golgi-localized guanine nucleotide exchange factors (GEFs) such as GBF1, BIG1/2, and CYTH proteins, whereas GTP hydrolysis is stimulated by ARF GTPase-activating proteins (GAPs) including ArfGAP1 and ASAP1. In its GTP-bound state, ARF5 recruits the coatomer complex (COPI) and adaptor protein AP-1 to Golgi membranes, driving vesicle budding and cargo sorting. ARF5 also interacts with cargo receptors, SNARE proteins, and phosphoinositide kinases, thereby coordinating retrograde transport from the Golgi to the endoplasmic reticulum, maintaining Golgi architecture, and regulating secretory and endosomal trafficking pathways.
In the A-549 lung adenocarcinoma context, ARF5 knockout is expected to perturb Golgi integrity and vesicular trafficking, potentially affecting secretion of oncogenic factors, cell surface receptor localization, and integrin-mediated adhesion. Given ARF5’s role in COPI vesicle formation, its disruption may alter the trafficking of growth factor receptors and matrix metalloproteinases, influencing cancer cell proliferation, migration, and drug sensitivity. This model thus provides a valuable platform to explore how Golgi-centered trafficking impacts malignant phenotypes and therapeutic responses.
Researchers can employ the ARF5 Knockout A-549 Polyclonal Cells in a range of functional assays, including immunofluorescence staining of Golgi markers such as GM130 and giantin to assess structural changes, protein secretion assays to evaluate constitutive and regulated exocytosis, and Western blotting for downstream effectors like COPI subunits. Additionally, the model is suited for cell viability and migration/invasion assays under various drug treatments, enabling investigation into ARF5’s contribution to cancer cell survival and metastasis. These polyclonal cells also facilitate co-culture and signaling studies to map ARF5-dependent intracellular protein sorting. For detailed experimental protocols and technical support, contact Ascent Research.
